Effect of Exercise in OI
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00770484|
Recruitment Status : Completed
First Posted : October 10, 2008
Results First Posted : July 9, 2015
Last Update Posted : August 5, 2016
The main limitation patients with orthostatic intolerance (OI, or postural tachycardia syndrome, POTS) have to exercise is related to their increase in heart rate when standing. Main pharmacological treatment today is aimed at reducing heart rate with the use of betablockers (propanolol), this theoretically could also improve their exercise capacity; if their heart rate do not increase as much with the medication, they could exercise more. In addition, it has been suggested that in healthy volunteers subjected to head down tilt for 2 weeks (situation that produces a "simulated" transient POTS-like state) a single bout of intense exercise can improve orthostatic tolerance the day after exercising. The mechanisms involved in such response are not that clear but could be an increase in plasma volume already diminished in POTS patients. It seems likely that the same could be true for POTS patients.
The purpose of the present study are to pharmacologically improve the amount of exercise POTS patients can perform by reducing their baseline heart rate (specific aim 1) and to evaluate next day heart responses to an acute bout of intense exercise.
Therefore, the specific aims of this study are:
- To test the hypothesis that lowering heart rate response with propanolol will result in an increase in exercise capacity.
- To test the hypothesis that a single bout of exercise will result in an improvement in orthostatic tolerance the day after exercising.
|Condition or disease||Intervention/treatment|
|Orthostatic Intolerance Postural Tachycardia Syndrome||Drug: Propranolol then Placebo Drug: Placebo then Propranolol|
- Subjects will be studied twice, once after receiving placebo and in a second occasion after receiving propanolol.
- An exercise capacity test with estimation of maximal oxygen consumption (VO2 max) will be done within 1 hour of receiving a pill containing placebo and that will be in appearance identical to the one for propanolol. This test will be conducted on a stationary bicycle and the effort will be gradually increased while expired air is measured during exhaustive physical work. The test will last approximately 30 minutes and be conducted in Vanderbilt's Clinical Trial Center.
- The day before and the day after the exercise test subjects will be asked to collect urine for 12 hours each time and to keep a record of how much liquid they ingest.
- Posture study tests (measurements of heart rate and blood pressure taken while lying down and at intervals for up to 30 minutes while standing) will be done the day before and the day after the exercise test.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effects of Exercise in Orthostatic Intolerance|
|Study Start Date :||November 2008|
|Primary Completion Date :||May 2015|
|Study Completion Date :||May 2015|
Experimental: Propranolol then placebo
Drug: Propranolol then Placebo
Propanolol 20 mg, given orally within 1 hour prior to exercising
Other Name: Active
Placebo Comparator: Placebo then propranolol
Drug: Placebo then Propranolol
Placebo, matching pill given orally within 1 hour prior to exercising
Other Name: Inactive
- Maximal Oxygen Consumption Capacity (VO2 Max) [ Time Frame: Over approximately 30 minutes, within 2 hours of receiving each intervention. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00770484
|United States, Tennessee|
|Vanderbilt University Medical Center|
|Nashville, Tennessee, United States, 37232|
|Principal Investigator:||Italo Biaggioni, MD||Vanderbilt University|